Other studies identified similarly low frequencies of ERBB2 amplification (21%–32%) in ctDNA from HER2+ BC and detected other common BC amplifications (including CCND1, FGFR1) at significantly lower frequencies in ctDNA compared with matched tissue [7, 13]. This evidence concerns the gene CCND1 and breast cancer.